Evidence map›Paper›PMID 35563408›Full record

ArticleInternational journal of molecular sciences2022

An Antisense Oligonucleotide against a Splicing Enhancer Sequence within Exon 1 of the

Kazuhiro Maeta, Manal Farea, Hisahide Nishio, Masafumi Matsuo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Expansion of Splice-Switching Therapy with Antisense Oligonucleotides.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kazuhiro MaetaKNC Department of Nucleic Acid Drug Discovery, Faculty of Rehabilitation, Kobe Gakuin University, Kobe 651-2180, Hyogo, Japan.
Manal FareaKNC Department of Nucleic Acid Drug Discovery, Faculty of Rehabilitation, Kobe Gakuin University, Kobe 651-2180, Hyogo, Japan.
Hisahide NishioResearch Center for Locomotion Biology, Kobe Gakuin University, Kobe 651-2180, Hyogo, Japan.ORCID 0000-0002-6778-4511
Masafumi MatsuoKNC Department of Nucleic Acid Drug Discovery, Faculty of Rehabilitation, Kobe Gakuin University, Kobe 651-2180, Hyogo, Japan.
Kobe Gakuin University · JP

Funding

Japan Agency for Medical Research and Development 20ek0109442h0001Japan Society for the Promotion of Science 21K07762, 18K07861
6 · The paper itself

Abstract

Antisense oligonucleotides (ASOs) are agents that modulate gene function. ASO-mediated out-of-frame exon skipping has been employed to suppress gene function. Myostatin, encoded by the

Indexed as

MyostatinOligonucleotides, AntisenseBone Morphogenetic ProteinsEnhancer Elements, GeneticExonsGrowth Differentiation FactorsHumansMuscle, SkeletalRNA, MessengerRNA PrecursorsBone Morphogenetic ProteinsGDF11 protein, humanGrowth Differentiation FactorsMSTN protein, humanMyostatinOligonucleotides, AntisenseRNA, MessengerRNA Precursorsantisense oligonucleotidemyostatinsplicingsplicing enhancer sequence

Identifiers

PMID35563408
PMCPMC9101285
OpenAlexW4225256710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.